IMRN vs. HUGE, EDSA, PIRS, AVTX, RDHL, MNPR, KPRX, PPBT, COCP, and IMNN
Should you be buying Immuron stock or one of its competitors? The main competitors of Immuron include FSD Pharma (HUGE), Edesa Biotech (EDSA), Pieris Pharmaceuticals (PIRS), Avalo Therapeutics (AVTX), RedHill Biopharma (RDHL), Monopar Therapeutics (MNPR), Kiora Pharmaceuticals (KPRX), Purple Biotech (PPBT), Cocrystal Pharma (COCP), and Imunon (IMNN). These companies are all part of the "pharmaceutical preparations" industry.
Immuron (NASDAQ:IMRN) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.
Immuron has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Immuron received 187 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 67.75% of users gave Immuron an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
Immuron has higher revenue and earnings than FSD Pharma.
In the previous week, FSD Pharma had 8 more articles in the media than Immuron. MarketBeat recorded 9 mentions for FSD Pharma and 1 mentions for Immuron. FSD Pharma's average media sentiment score of 0.75 beat Immuron's score of 0.00 indicating that FSD Pharma is being referred to more favorably in the news media.
0.1% of Immuron shares are held by institutional investors. Comparatively, 1.2% of FSD Pharma shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 8.5% of FSD Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Immuron's return on equity of 0.00% beat FSD Pharma's return on equity.
Summary
Immuron beats FSD Pharma on 7 of the 11 factors compared between the two stocks.
Get Immuron News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
